Breaking the Repetition Barrier —
LM-VS™’s Shortcut to Discovery
In the early stages of drug discovery, researchers go through countless experiments to identify promising candidate compounds. This process consumes a great deal of time and resources.
LM-VS™ minimizes trial-and-error by narrowing down the compound pool through AI-based virtual screening and structure-based Designed Scaffold modeling, leading to faster, more cost-effective candidate selection.
Syntekabio’s Role
in the Drug Discovery Journey
LM-VS™ is a core platform for hit discovery in small molecule drug research, designed to rapidly and precisely identify promising candidates from vast compound libraries.
Subsequent stages can be seamlessly connected with DeepMatcher® and ALGO™ to accelerate and streamline the drug development journey.
The Power of AI & Structural Design —
Accelerating Drug Discovery
LM-VS™ drastically accelerates the discovery of new drug candidates by screening massive chemical compound libraries using AI prediction models trained on 3D protein structure data.
The platform evaluates molecular structures with an AI model, then applies structural knowledge through Designed Scaffold to generate new molecules optimized for the target.
By minimizing repetitive experiments and maximizing efficiency, LM-VS™ has successfully identified hits within just a few months — a process that traditionally would have taken several years.
Core Process of LM-VS™
LM-VS™ streamlines the early-stage drug discovery process with AI,
enabling fast and precise identification of potential drug candidates.
Key Application Areas
LM-VS™ is being applied in a wide range of research and development contexts by pharma and biotech companies.
Below are examples of how the platform is helping reshape drug discovery across diverse use cases:
